Quantitating therapeutically relevant T-cell responses to cancer vaccines.

Published

Journal Article (Review)

Successful application of active immunotherapy to the treatment of cancer will require stimulation of potent antigen-specific T-cell responses. It is not known how numerous or how potent these T cells must be in order to abrogate tumors, but the levels of immunity needed to control chronic viral infections may provide estimates for comparison. Evaluation of the efficacy of a vaccine strategy in attaining these levels of immunity will depend on the use of assays that create a picture of T-cell number and function that correlates with clinical outcomes. We discuss the currently available in vivo and in vitro T-cell assays and their relevance for detecting therapeutic levels of T-cell activity. We also propose a strategy for efficiently evaluating the immunologic efficacy of cancer vaccines so that the most promising candidates can be brought more rapidly into definitive clinical trials.

Full Text

Duke Authors

Cited Authors

  • Hobeika, AC; Clay, TM; Mosca, PJ; Lyerly, HK; Morse, MA

Published Date

  • January 2001

Published In

Volume / Issue

  • 21 / 1-3

Start / End Page

  • 287 - 297

PubMed ID

  • 11642610

Pubmed Central ID

  • 11642610

International Standard Serial Number (ISSN)

  • 1040-8401

Language

  • eng